Alison M Paterson
Overview
Explore the profile of Alison M Paterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1093
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borges T, Murakami N, Lape I, Gassen R, Liu K, Cai S, et al.
JCI Insight
. 2021 Nov;
6(24).
PMID: 34752418
The programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway is a potent inhibitory pathway involved in immune regulation and is a potential therapeutic target in transplantation. In this study, we...
2.
Peluso M, Adam A, Armet C, Zhang L, OConnor R, Lee B, et al.
J Immunother Cancer
. 2020 Apr;
8(1).
PMID: 32345627
Background: CD47 is a broadly expressed cell surface glycoprotein associated with immune evasion. Interaction with the inhibitory receptor signal regulatory protein alpha (SIRPα), primarily expressed on myeloid cells, normally serves...
3.
Paterson A, Lovitch S, Sage P, Juneja V, Lee Y, Trombley J, et al.
J Exp Med
. 2015 Sep;
212(10):1603-21.
PMID: 26371185
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essential negative regulator of T cell responses. Germline Ctla4 deficiency is lethal, making investigation of the function of CTLA-4 on mature T cells...
4.
Khor B, Gagnon J, Goel G, Roche M, Conway K, Tran K, et al.
Elife
. 2015 May;
4.
PMID: 25998054
The balance between Th17 and T regulatory (Treg) cells critically modulates immune homeostasis, with an inadequate Treg response contributing to inflammatory disease. Using an unbiased chemical biology approach, we identified...
5.
Sage P, Paterson A, Lovitch S, Sharpe A
Immunity
. 2014 Dec;
41(6):1026-39.
PMID: 25526313
The receptor CTLA-4 has been implicated in controlling B cell responses, but the mechanisms by which CTLA-4 regulates antibody production are not known. Here we showed deletion of CTLA-4 in...
6.
Liu S, Sutherland A, Zhang Z, Rainbow D, Quintana F, Paterson A, et al.
J Immunol
. 2011 Nov;
188(1):155-62.
PMID: 22124121
CTLA-4 is a potent inhibitor of T cell activation, primarily upon binding to its costimulatory ligands (B7.1 and B7.2) expressed on APCs. However, variants of CTLA-4 can also function independently...
7.
Paterson A, Brown K, Keir M, Vanguri V, Riella L, Chandraker A, et al.
J Immunol
. 2011 Jun;
187(3):1097-105.
PMID: 21697456
Programmed death-1 ligand 1 (PD-L1) is a coinhibitory molecule that negatively regulates multiple tolerance checkpoints. In the NOD mouse model, PD-L1 regulates the development of diabetes. PD-L1 has two binding...
8.
Yang J, Riella L, Chock S, Liu T, Zhao X, Yuan X, et al.
J Immunol
. 2011 Jun;
187(3):1113-9.
PMID: 21697455
The programmed death ligand 1 (PDL1)/programmed death 1 (PD1) costimulatory pathway plays an important role in the inhibition of alloimmune responses as well as in the induction and maintenance of...
9.
Farquhar C, Paterson A, Cobbold S, Garcia Rueda H, Fairchild P, Yates S, et al.
Eur J Immunol
. 2010 Apr;
40(6):1728-37.
PMID: 20373289
Pharmacological modulation is known to temper the immune capacity of DC, enhancing the notion that modulated Ag-bearing DC might be used therapeutically to induce tolerance. We have investigated phenotypic features...
10.